<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03549871</url>
  </required_header>
  <id_info>
    <org_study_id>EFC15110</org_study_id>
    <secondary_id>2016-004087-19</secondary_id>
    <secondary_id>ALN-AT3SC-009</secondary_id>
    <secondary_id>U1111-1217-3270</secondary_id>
    <nct_id>NCT03549871</nct_id>
  </id_info>
  <brief_title>A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis</brief_title>
  <acronym>ATLAS-PPX</acronym>
  <official_title>ATLAS-PPX: an Open-label, Multinational, Switching Study to Describe the Efficacy and Safety of Fitusiran Prophylaxis in Patients With Hemophilia A and B Previously Receiving Factor or Bypassing Agent Prophylaxis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To characterize the frequency of bleeding episodes while receiving fitusiran treatment,&#xD;
      relative to the frequency of bleeding episodes while receiving factor or bypassing agent&#xD;
      (BPA) prophylaxis&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To characterize the following while receiving fitusiran treatment, relative to receiving&#xD;
           factor or BPA prophylaxis:&#xD;
&#xD;
        -  the frequency of spontaneous bleeding episodes&#xD;
&#xD;
        -  the frequency of joint bleeding episodes&#xD;
&#xD;
        -  health related quality of life (HRQOL) in patients ≥17 years of age&#xD;
&#xD;
        -  To characterize the frequency of bleeding episodes during the onset and treatment&#xD;
           periods in patients receiving fitusiran&#xD;
&#xD;
        -  To characterize the safety and tolerability of fitusiran&#xD;
&#xD;
        -  Annualized weight-adjusted consumption of factor/BPA&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study duration per participant is approximately 13 months including 6-Month factor or BPA&#xD;
      prophylaxis period and 7-Month fitusiran treatment period. Study duration for patients in the&#xD;
      subgroup of Cohort A is approximately 7 months corresponding to a 7-Month fitusiran treatment&#xD;
      period.&#xD;
&#xD;
      Participants completing the treatment period will be proposed to enroll in an extension study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 30, 2018</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized bleeding rate (ABR)</measure>
    <time_frame>13 months (6 months in factor/BPA prophylaxis period and fitusiran baseline to end of study which includes one month onset period and 6 months efficacy period)</time_frame>
    <description>Annualized Bleeding Rate (ABR) in the fitusiran efficacy period and the factor or BPA prophylaxis period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annualized spontaneous bleeding rate</measure>
    <time_frame>13 months (6 months in factor/BPA prophylaxis period and fitusiran baseline to end of study which includes one month onset period and 6 months efficacy period)</time_frame>
    <description>Annualized spontaneous bleeding rate in the fitusiran efficacy period and the factor or BPA prophylaxis period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized joint bleeding rate</measure>
    <time_frame>13 months (6 months in factor/BPA prophylaxis period and fitusiran baseline to end of study which includes one month onset period and 6 months efficacy period)</time_frame>
    <description>Annualized joint bleeding rate in the fitusiran efficacy period and the factor or BPA prophylaxis period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL) as measured by Haem-A-QOL Questionnaire score on a scale of 0-100 with higher scores representing greater impairment</measure>
    <time_frame>7 months</time_frame>
    <description>Change in Haem-A-QOL physical health score and total score in the fitusiran treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ABR in the onset period</measure>
    <time_frame>1 months</time_frame>
    <description>ABR in the fitusiran onset period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ABR in the treatment period</measure>
    <time_frame>7 months</time_frame>
    <description>ABR in the fitusiran treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized weight-adjusted consumption of factor/BPA</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients reported with adverse events</measure>
    <time_frame>13 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Hemophilia</condition>
  <arm_group>
    <arm_group_label>Fitusiran</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fitusiran sub-cutaneous injection for 7 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fitusiran</intervention_name>
    <description>Pharmaceutical form: solution for injection Route of administration: subcutaneous</description>
    <arm_group_label>Fitusiran</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males, ≥12 years of age&#xD;
&#xD;
          -  Severe hemophilia A or B (as evidenced by a central laboratory measurement at&#xD;
             screening or documented medical record evidence of FVIII &lt;1% or FIX level ≤2%)&#xD;
&#xD;
          -  A minimum of 2 bleeding episodes requiring BPA treatment within the last 6 months&#xD;
             prior to Screening for patients with inhibitory antibodies to factor VIII or factor IX&#xD;
             (Cohort A). A minimum of 1 bleeding episode requiring factor treatment within the last&#xD;
             12 months prior to Screening for patients without inhibitory antibodies to factor VIII&#xD;
             or factor IX (Cohort B).&#xD;
&#xD;
          -  Must meet either the definition of inhibitor or non-inhibitor patient as below:&#xD;
&#xD;
          -  Inhibitor:Use of BPAs for prophylaxis and for any bleeding episodes for at least the&#xD;
             last 6 months prior to Screening, and meet one of the following Nijmegen-modified&#xD;
             Bethesda assay results criteria:&#xD;
&#xD;
          -  Inhibitor titer of ≥0.6 BU/mL at Screening, or&#xD;
&#xD;
          -  Inhibitor titer of &lt;0.6 BU/mL at Screening with medical record evidence of 2&#xD;
             consecutive titers ≥0.6 BU/mL, or&#xD;
&#xD;
          -  Inhibitor titer of &lt;0.6 BU/mL at Screening with medical record evidence of anamnestic&#xD;
             response&#xD;
&#xD;
          -  The subgroup of patients in Cohort A patients must additionally meet the following&#xD;
             criteria to be eligible to start treatment with fitusiran directly after the screening&#xD;
             period:&#xD;
&#xD;
               -  Hemophilia B with inhibitory antibody to Factor IX as defined above&#xD;
&#xD;
               -  Not responding adequately to BPA treatment (historical ABR ≥20) prior to&#xD;
                  enrollment&#xD;
&#xD;
               -  In the opinion of the Investigator, with approval of Sponsor Medical Monitor,&#xD;
                  6-month BPA prophylaxis period should be omitted.&#xD;
&#xD;
          -  Non-inhibitor:Use of factor concentrates for prophylaxis and for any bleeding episodes&#xD;
             for at least the last 6 months prior to Screening, and meet each of the following&#xD;
             criterion:&#xD;
&#xD;
          -  Nijmegen-modified Bethesda assay inhibitor titer of &lt;0.6 BU/mL at Screening and&#xD;
&#xD;
          -  No use of bypassing agents to treat bleeding episodes for at least the last 6 months&#xD;
             prior to Screening and&#xD;
&#xD;
          -  No history of immune tolerance induction therapy within the past 3 years prior to&#xD;
             Screening.&#xD;
&#xD;
          -  Documented prophylactic treatment with factor concentrates or bypassing agents for the&#xD;
             treatment of hemophilia A or B for at least 6 months prior to Screening&#xD;
&#xD;
          -  Adherent to the prescribed prophylactic therapy for at least 6 months prior to&#xD;
             Screening per Investigator assessment&#xD;
&#xD;
          -  Willing and able to comply with the study requirements and to provide written informed&#xD;
             consent and assent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known co-existing bleeding disorders other than hemophilia A or B&#xD;
&#xD;
          -  AT activity &lt;60% at Screening&#xD;
&#xD;
          -  Co-existing thrombophilic disorder&#xD;
&#xD;
          -  Clinically significant liver disease&#xD;
&#xD;
          -  Active Hepatitis C virus infection&#xD;
&#xD;
          -  Acute or chronic Hepatitis B virus infection&#xD;
&#xD;
          -  HIV positive with a CD4 count of &lt;200 cells/μL&#xD;
&#xD;
          -  History of arterial or venous thromboembolism&#xD;
&#xD;
          -  Inadequate renal function&#xD;
&#xD;
          -  History of multiple drug allergies or history of allergic reaction to an&#xD;
             oligonucleotide or N-Acetylgalactosamine (GalNAc)&#xD;
&#xD;
          -  History of intolerance to SC injection(s)&#xD;
&#xD;
          -  Any other conditions or comorbidities that would make the patient unsuitable for&#xD;
             enrollment or could interfere with participation in or completion of the study, per&#xD;
             Investigator judgment&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 0140</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0141</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0139</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 0111</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6101</name>
      <address>
        <city>Camperdown</city>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6104</name>
      <address>
        <city>Prahran</city>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1102</name>
      <address>
        <city>Montreal</city>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1103</name>
      <address>
        <city>Vancouver</city>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8604</name>
      <address>
        <city>Beijing</city>
        <zip>100045</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4501</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3303</name>
      <address>
        <city>Lyon</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3305</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 5301</name>
      <address>
        <city>Crumlin</city>
        <zip>12</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 9701</name>
      <address>
        <city>Ramat-Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 3902</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8108</name>
      <address>
        <city>Kashihara</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8103</name>
      <address>
        <city>Kitakyushu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8101</name>
      <address>
        <city>Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8102</name>
      <address>
        <city>Nishinomiya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8104</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8110</name>
      <address>
        <city>Suginami</city>
        <zip>1670035</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8109</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8201</name>
      <address>
        <city>Busan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8202</name>
      <address>
        <city>Daejeon</city>
        <zip>35233</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8204</name>
      <address>
        <city>Seoul</city>
        <zip>3722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6004</name>
      <address>
        <city>Ampang</city>
        <zip>68000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6002</name>
      <address>
        <city>Johor Bahru</city>
        <zip>80100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6003</name>
      <address>
        <city>Kota Kinabalu</city>
        <zip>88586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 9002</name>
      <address>
        <city>Adana</city>
        <zip>?01130</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 9001</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 9004</name>
      <address>
        <city>Antalya</city>
        <zip>07059</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 9008</name>
      <address>
        <city>Gaziantep</city>
        <zip>27100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 9005</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 9010</name>
      <address>
        <city>İzmir</city>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 9003</name>
      <address>
        <city>Izmir</city>
        <zip>TR-35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 9009</name>
      <address>
        <city>Kayseri</city>
        <zip>38039</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 9006</name>
      <address>
        <city>Samsun</city>
        <zip>55200</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site number 9013</name>
      <address>
        <city>Van</city>
        <zip>65080</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8003</name>
      <address>
        <city>Kyiv</city>
        <zip>?01135</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8002</name>
      <address>
        <city>Lviv</city>
        <zip>79044</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4402</name>
      <address>
        <city>Glasgow</city>
        <zip>G4 0SF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4407</name>
      <address>
        <city>London</city>
        <zip>E1 2ES</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4403</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 4401</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>China</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
    <country>South Africa</country>
    <country>Spain</country>
  </removed_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 25, 2018</study_first_submitted>
  <study_first_submitted_qc>June 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2018</study_first_posted>
  <last_update_submitted>March 26, 2021</last_update_submitted>
  <last_update_submitted_qc>March 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

